First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With <scp>PR</scp>: A Case Report
This case underscores the potential of icaritin as a therapeutic option for HCC patients with compromised health status. The combination of icaritin and thalidomide demonstrated promising efficacy in this real-world scenario. Multidisciplinary combination treatment strategies incorporating icaritin merit further exploration, given its immunomodulatory effects and favorable safety profile.
Authors
- Fei Zhou (ORCID: https://orcid.org/0000-0001-6657-7433)
- H. Li (ORCID: https://orcid.org/0009-0002-8176-2420)
- Zhuo Wang (ORCID: https://orcid.org/0000-0002-2394-8684)
- Zhi‐Cheng Jin (ORCID: https://orcid.org/0000-0002-6114-154X)
Institutions
- Jilin City Central Hospital (CN)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cnr2.70136
- Primary Topic
- Medicinal Plant Pharmacodynamics Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00